Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Cardiovascular Endocrinology

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1565385

This article is part of the Research TopicMetabolic Pathways to Multiple Long-term Conditions (Multimorbidity): Focusing on Cardio-metabolic Multimorbidity (CMM)View all 10 articles

The expression profiles and roles of microRNAs in cardiac glucose metabolism

Provisionally accepted
Hua  QianHua QianYa-Fang  ZhuYa-Fang ZhuNan-Nan  ShenNan-Nan Shen*
  • The Affiliated Hospital of Shaoxing University, Shaoxing, China

The final, formatted version of the article will be published soon.

Background: MicroRNAs (miRNAs) are a class of endogenous, non-coding RNAs, that have been implicated in cardiovascular diseases. Recent studies have suggested that dysregulated miRNAs accumulate in the heart and may be associated with impaired cardiac glucose metabolism. However an inconsistent direction of expression was observed in the current available literature. The aim of this study was to characterize miRNA expression profiles associated with glucose metabolism, and to explore their potential as biomarkers for glucose metabolism disorders in diabetic cardiomyopathy (DCM).Methods: A systematic search of electronic databases, including Embase, PubMed, and the Cochrane Library, was conducted until October 1, 2024. Studies reporting on miRNAs expression profiles that regulate glucose metabolism in the heart were selected for inclusion. Pooled results were presented as log10 odds ratios (logORs) with 95% confidence intervals (CIs), using random-effect models. Subgroup analyses were conducted based on species, region, and sample source. Analyses by species focused specifically on humans and mice. The quality of included articles was assessed using the modified Diagnostic Accuracy Study 2 (QUADAS-2) tool. Results: A total of 47 eligible articles were included in this study, identifying 70 dysregulated miRNAs. Further analysis revealed that compared with the non-DCM group, the DCM group exhibited differential miRNA expression, with 12 miRNAs consistently upregulated and 8 consistently downregulated. Among these miRNAs, miR-199a (logOR 4.59; 95% CI: 3.02-6.15) was the most upregulated and frequently reported (n=7 studies), while let-7 (logOR 4.48; 95% CI: 2.41-6.55) was the most downregulated (4 studies). Subgroup analysis indicated that miRNA-21 was the most upregulated in cardiac tissue, and miRNA-133 was the most downregulated in cardiomyocytes. Additionally, miRNA-21 was found to be the most upregulated across different species. In the region subgroups, miRNA-199a and miRNA-503 were the most upregulated and downregulated in Asian countries, whereas miRNA-378 was the most dysregulated in non-Asian countries.In summary, this study identified 20 consistently dysregulated miRNAs assocaited with myocardial glucose metabolism. Six dysregulated miRNAs, including miRNA-199a, let-7, miRNA-21, miRNA-133, miRNA-503 and miRNA-378, have potential as candidate miRNA biomarkers of glycometabolism in the heart. These findings require further validation in future larger-scale studies.

Keywords: miRNAs, Heart, glucose metabolism, Systematic review, biomarker

Received: 23 Jan 2025; Accepted: 30 Jun 2025.

Copyright: © 2025 Qian, Zhu and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Nan-Nan Shen, The Affiliated Hospital of Shaoxing University, Shaoxing, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.